The CINP International Scientific Programme Committee is pleased to announce the following debate speakers for the 2020 CINP World Congress.
Friday 26 June 2020
Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center. Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research. Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari, Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998. Dr Gobbi’s lab is interested in understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain. Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology. She has received several fellowships for more than $10M as a principal investigator. She has won many prizes including the Canadian College of Neuropsychopharmacology (CCNP) Young investigator Award in 2012, the Venezia Prize in 2015 and the Sam Lal prize from the Boeckh Foundation in 2017. She has served as reviewer/editor for many journals, international grant agencies in Europe and the USA and has been invited to speak at conferences around the world.
David Nutt is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology at Imperial College London. He was previously President of the European Brain Council, the British Association of Psychopharmacology, the British Neuroscience Association and the European College of Neuropsychopharmacology.
Saturday June 27 2020
Topic: Is long-term treatment with antipsychotics justified?
Konstantinos N. Fountoulakis, MD, is Professor of Psychiatry at Aristotle University of Thessaloniki, AHEPA University Hospital, in Thessaloniki, Greece. He has coauthored more than 400 papers and more than 250 of them are published in high impact international journals with approx. 10,000 citations and h=50 (Publish or Perish). During the years 2016-8, he was ranked by expertscape.com within the top 25 world experts concerning Bipolar disorder (0.068%) and among the top 50 concerning suicidality (0.097%). He authored or co-authored a number of chapters in books, the book ‘Bipolar disorders: An Evidence-Based Guide to Manic Depression’ (Springer-Verlag 2015), co-edited the WPA book ‘Advances in Psychiatry vol 3’ (Springer-Verlag 2018), and the book ‘Psychobiology of behavior’ (Springer-Verlag 2019). He has received a number of national and international research awards, including the 2012 Kraepelin-Alzheimer medal of the University of Munich and the 2015 Excellence in Education Award of the WFSBP. Since 2014, he has been an honorary member of the WPA.
Robin Murray is Professor of Psychiatric Research at the Institute of Psychiatry, London. He was one of the first to suggest that schizophrenia was in part a neurodevelopmental disorder, and he has contributed to the understanding that environmental factors such as obstetric events, drug abuse and social adversity increase the risk of psychosis. He is the most frequently cited psychosis researcher outside the USA, has supervised 72 PhDs and 12 MD Theses, and 40 of his students have become full professors. He was elected a Fellow of the Royal Society in 2010 and received a knighthood in 2011.
Sunday June 28 2020
Topic: Pharmacogenetics guides psychiatric treatments VS The barriers for the use of pharmacogenetics
Alessandro Serretti is the Associate Professor of Psychiatry at Bologna University, Italy. Coordinator of research in clinical and genetic studies of major psychoses. Author of 550 peer reviewed papers, one textbook of psychiatry and over 650 presentations at meetings. H-Index of 83. Reviewer or member of the editorial board for 170 journals and funding agencies.
Henk-Jan Guchelaar studied Pharmacy at the Rijksuniversiteit Groningen (RuG) and specialized as a hospital pharmacist and clinical pharmacologist. Since 2003, he is employed as a clinical pharmacist and clinical pharmacologist and professor of clinical pharmacy and chair of the department of Clinical Pharmacy & Toxicology at Leiden University Medical Center. Since October 2008, he is also appointed professor of Clinical Pharmacy at the Faculty of Science, Leiden Academic Center for Drug Research, University Leiden and chair of the Leiden University focus area ‘Translational Drug Discovery and Development’. Pharmaceutical patientcare in oncology is his main area of clinical interest. He is program leader of the research program ‘Personalised Therapeutics’ investigating interindividual variability of drug response with an emphasis on pharmacogenomics. He is founder and board member of the Leiden Network for Personalised Therapeutics (www.lnpt.nl). He is (co-)author of more than 500 (Web of Science indexed) articles (Pubmed: 360) in international peer reviewed scientific journals, more than 100 articles in Dutch journals and 20 (chapters in) books. Guchelaar is coordinator of the EU funded Horizon 2020 project Ubiquitous Pharmacogenomics (www.upgx.eu) aimed at implementing pre-emptive pharmacogenomic testing in the EU. From 2010-2016 he was a member of the national Central Committee on Research Involving Human Subjects, from 2003-2017, he was vice-chair of the Dutch Society for Clinical Pharmacology and Biopharmacy, and since 2016 he is member of the Dutch Medicines Evaluation Board. Since 2017, he is member of Council for Medical Sciences of the Royal Dutch Academy of Science. Henk-Jan is founder of the new Master of Pharmacy, Leiden University Medical Center, University of Leiden.
Join us in Taipei, Taiwan for the 32nd CINP World Congress of Neuropsychopharmacology. Your global platform for neuropsychopharmacology.
Keep up to date with Congress News & Alerts